---
title: "Analyst Reiterates Buy on Black Diamond Therapeutics, Citing Differentiated EGFR Inhibitor and Strong Cash Runway Through 2028"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285630631.md"
description: "TD Cowen analyst Marc Frahm has reiterated a Buy rating on Black Diamond Therapeutics (BDTX) stock, citing its differentiated EGFR inhibitor, silevertinib (BDTX-1535), and a strong cash position of approximately $118 million, which supports operations through 2028. He anticipates that upcoming ASCO data will enhance the drug's competitiveness. Additionally, a Phase 2 trial in EGFR-mutant GBM is set to provide further value, while potential partnerships for NSCLC could offer long-term benefits. H.C. Wainwright also maintains a Buy rating with an $11.00 price target."
datetime: "2026-05-07T22:25:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285630631.md)
  - [en](https://longbridge.com/en/news/285630631.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285630631.md)
---

# Analyst Reiterates Buy on Black Diamond Therapeutics, Citing Differentiated EGFR Inhibitor and Strong Cash Runway Through 2028

TD Cowen analyst Marc Frahm has maintained their bullish stance on BDTX stock, giving a Buy rating on April 29.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Marc Frahm has given his Buy rating due to a combination of factors tied to Black Diamond Therapeutics’ lead asset and financial position. He highlights silevertinib (BDTX-1535) as a differentiated, CNS-penetrant EGFR inhibitor with broad activity across non-classical EGFR-mutant NSCLC, including strong responses in brain metastases, and sees upcoming ASCO DOR/PFS data as a key catalyst that could reinforce its competitiveness despite prior concerns about dose reductions and rival therapies.

He also notes that the company’s cash balance of roughly $118 million provides runway into the second half of 2028, supporting both regulatory interactions and clinical execution. In parallel, the initiation of a randomized Phase 2 trial in EGFR-mutant GBM, with PFS data expected in the first half of 2028, offers an additional value driver, and potential partnership structures for a pivotal NSCLC program could preserve long-term upside, collectively justifying a continued Buy stance.

In another report released on April 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $11.00 price target.

### Related Stocks

- [BDTX.US](https://longbridge.com/en/quote/BDTX.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)

## Related News & Research

- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [BeOne Medicines’ BEQALZI™ (sonrotoclax) Approved by U.S. FDA as First and Only BCL2 Inhibitor for R/R Mantle Cell Lymphoma | ONC Stock News](https://longbridge.com/en/news/286297796.md)
- [BeOne Medicines Wins Conditional FDA Nod For Cancer Drug In Rare Blood Cancer](https://longbridge.com/en/news/286453582.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [BeOne Wins First-in-Class U.S. FDA Nod for BCL2 Drug in Relapsed Mantle Cell Lymphoma](https://longbridge.com/en/news/286330888.md)